Fatal arterial hemorrhage after pancreaticoduodenectomy: How do we simultaneously accomplish complete hemostasis and hepatic arterial flow?

Table 4 Clinical course and outcome after endovascular treatment

Case number	Complication after EVT	Liver infarction after EVT	Hospital death (day number1 and POD)	Clinical success2	Follow-up term (yr)	Cause of death	Prognosis (dead or alive)
1	-	No	No	Yes	5.57	Cancer-related death	Dead
2	-	No	Yes (+ 61 and 94)	Yes	0.26	Cancer-related death	Dead
3	-	No	No	Yes	0.72	Cancer-related death	Dead
4	-	No	No	Yes	8.36	-	Alive
5	-	No	No	Yes	0.56	Cancer-related death	Dead
6	Bleeding	No	No	Yes	1.04	Cancer-related death	Dead
7	-	No	No	Yes	1.34	Cancer-related death	Dead
8	-	No	No	Yes	0.52	Cancer-related death	Dead
9	-	No	No	Yes	0.47	Cancer-related death	Dead
10	-	No	No	Yes	1.95	-	Alive
11	-	No	No	Yes	1.69	-	Alive
12	-	No	No	Yes	1.46	-	Alive
13	-	Yes	No	Yes	1.74	Cancer-related death	Dead
14	Bleeding; Liver abscess	Yes	No	Yes	9.55	-	Alive
15	-	No	Yes (+ 1 and 14)	No	0.04	Bleeding, sepsis and DIC	Dead
16	-	No	Yes (+ 3 and 31)	No	0.08	Liver failure	Dead

¹The day number from the initial EVT.

²Short-term clinical outcome. EVT: Endovascular treatment; DIC: Disseminated intravascular coagulation; POD: Postoperative day after pancreaticoduodenectomy.